CN114222741B - 作为p2x3抑制剂的吡啶并嘧啶类衍生物 - Google Patents

作为p2x3抑制剂的吡啶并嘧啶类衍生物

Info

Publication number
CN114222741B
CN114222741B CN202080038831.1A CN202080038831A CN114222741B CN 114222741 B CN114222741 B CN 114222741B CN 202080038831 A CN202080038831 A CN 202080038831A CN 114222741 B CN114222741 B CN 114222741B
Authority
CN
China
Prior art keywords
pyrimidin
pyrido
amine
fluorophenyl
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080038831.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN114222741A (zh
Inventor
P·布鲁诺
M·比亚杰蒂
C·费奥莱里
C·贝克-格伦
H·范德波尔
S·D·派恩鲁斯
R·拉那罗
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chiesi Farmaceutici SpA
Original Assignee
Chiesi Farmaceutici SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farmaceutici SpA filed Critical Chiesi Farmaceutici SpA
Publication of CN114222741A publication Critical patent/CN114222741A/zh
Application granted granted Critical
Publication of CN114222741B publication Critical patent/CN114222741B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202080038831.1A 2019-05-31 2020-05-28 作为p2x3抑制剂的吡啶并嘧啶类衍生物 Active CN114222741B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP19177610.3 2019-05-31
EP19177610 2019-05-31
EP19201165.8 2019-10-02
EP19201165 2019-10-02
PCT/EP2020/064915 WO2020239953A1 (en) 2019-05-31 2020-05-28 Pyridopyrimidines derivatives as p2x3 inhibitors

Publications (2)

Publication Number Publication Date
CN114222741A CN114222741A (zh) 2022-03-22
CN114222741B true CN114222741B (zh) 2025-12-30

Family

ID=70857198

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080038831.1A Active CN114222741B (zh) 2019-05-31 2020-05-28 作为p2x3抑制剂的吡啶并嘧啶类衍生物

Country Status (11)

Country Link
US (1) US12606562B2 (cg-RX-API-DMAC7.html)
EP (1) EP3976609A1 (cg-RX-API-DMAC7.html)
JP (1) JP7797204B2 (cg-RX-API-DMAC7.html)
KR (1) KR102923602B1 (cg-RX-API-DMAC7.html)
CN (1) CN114222741B (cg-RX-API-DMAC7.html)
AU (1) AU2020281924B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021020279A2 (cg-RX-API-DMAC7.html)
CA (1) CA3136024A1 (cg-RX-API-DMAC7.html)
MA (1) MA56020A (cg-RX-API-DMAC7.html)
MX (1) MX2021014116A (cg-RX-API-DMAC7.html)
WO (1) WO2020239953A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA56022A (fr) 2019-05-31 2022-04-06 Chiesi Farm Spa Dérivés d'amino quinazoline servant d'inhibiteurs de p2x3
KR102923602B1 (ko) 2019-05-31 2026-02-06 키에시 파르마슈티시 엣스. 피. 에이. P2x3 억제제로서 피리도피리미딘 유도체
WO2022160931A1 (zh) * 2021-01-28 2022-08-04 浙江海正药业股份有限公司 吡啶并嘧啶类衍生物及其制备方法和用途
JP2026517300A (ja) 2023-05-22 2026-05-28 キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ P2x3阻害剤を調製するための方法および中間体
WO2026143058A1 (en) * 2024-12-23 2026-07-02 Neolaia Inc. Pyridopyrimidine compounds useful as cd38 inhibitors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011041655A1 (en) * 2009-10-01 2011-04-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Quinazolin-4-amine derivatives; and methods of use
CN109641886A (zh) * 2015-11-25 2019-04-16 康威基内有限公司 双环bet布罗莫结构域抑制剂及其用途
CN112739699A (zh) * 2018-07-25 2021-04-30 费斯制药股份有限公司 作为组胺h4受体抑制剂的吡啶并嘧啶化合物

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH31122A (en) 1993-03-31 1998-02-23 Eisai Co Ltd Nitrogen-containing fused-heterocycle compounds.
JP4342007B2 (ja) * 1998-08-10 2009-10-14 大日本住友製薬株式会社 キナゾリン誘導体
PT1725540E (pt) 2004-03-05 2012-11-29 Hoffmann La Roche Diaminopirimidinas como antagonistas de p2x3 e p2x2/3
SI1924264T1 (sl) * 2005-09-01 2013-12-31 F. Hoffmann-La Roche Ag Diaminopirimidini kot modulatorji p2x3 in p2x2/3
WO2007134986A1 (en) 2006-05-23 2007-11-29 F. Hoffmann-La Roche Ag Pyridopyrimidinone derivatives
ES2596706T3 (es) 2006-06-29 2017-01-11 F. Hoffmann-La Roche Ag Arilamidas con sustitución de tetrazol
TW200840584A (en) 2006-12-26 2008-10-16 Gilead Sciences Inc Pyrido(3,2-d)pyrimidines useful for treating viral infections
WO2008123963A1 (en) 2007-04-02 2008-10-16 Renovis, Inc. Pyrid-2-yl fused heterocyclic compounds, and compositions and uses thereof
US8076345B2 (en) 2007-04-17 2011-12-13 Evotec Ag 2-cyanophenyl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine compounds, compositions and uses thereof
WO2009110985A2 (en) 2008-02-29 2009-09-11 Renovis, Inc. Amide compounds, compositions and uses thereof
US20110237578A1 (en) 2008-09-18 2011-09-29 Zhi-Liang Wei Amide compounds, compositions and uses thereof
JP2012504157A (ja) 2008-09-30 2012-02-16 アストラゼネカ アクチボラグ 複素環式jakキナーゼ阻害剤
SG173647A1 (en) 2009-02-13 2011-10-28 Shionogi & Co Novel triazine derivative and pharmaceutical composition containing same
WO2012064973A2 (en) * 2010-11-10 2012-05-18 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP2938600B1 (en) 2012-12-27 2017-01-25 F. Hoffmann-La Roche AG Comt inhibitors
WO2016053794A1 (en) 2014-09-30 2016-04-07 Bristol-Myers Squibb Company Quinazoline-based kinase inhibitors
WO2016084922A1 (ja) 2014-11-28 2016-06-02 塩野義製薬株式会社 1,2,4-トリアジン誘導体およびその医薬組成物
WO2016088838A1 (ja) 2014-12-04 2016-06-09 塩野義製薬株式会社 プリン誘導体およびその医薬組成物
CU24411B1 (es) 2014-12-09 2019-05-03 Bayer Ag Compuesto derivado de benzamida sustituida con 1,3-tiazol-2-ilo útil para el tratamiento de trastornos neurogénicos
WO2017011729A1 (en) 2015-07-16 2017-01-19 Patara Pharma, LLC Combination therapies for the treatment of lung diseases
CA2998742C (en) 2015-09-29 2023-08-29 Anthony P. FORD Diaminopyrimidine p2x3 and p2x2/3 receptor modulators for use in the treatment of cough
CN106565684B (zh) 2016-03-18 2019-06-18 南方医科大学 6-吡唑取代喹唑啉类化合物及其衍生物、合成方法及其应用
JP6776378B2 (ja) 2016-06-30 2020-10-28 ギリアード サイエンシーズ, インコーポレイテッド Cotモジュレーターとしての4,6−ジアミノキナゾリン類およびその使用方法
GB201700814D0 (en) * 2017-01-17 2017-03-01 Liverpool School Tropical Medicine Compounds
TWI762634B (zh) 2017-05-05 2022-05-01 大陸商上海赫普化醫藥技術有限公司 胺基-芳基-苯甲醯胺化合物及其使用方法
CN109721554A (zh) 2019-01-08 2019-05-07 贵州大学 一类4-氨基喹唑啉类化合物及其制备方法和应用
MA56022A (fr) * 2019-05-31 2022-04-06 Chiesi Farm Spa Dérivés d'amino quinazoline servant d'inhibiteurs de p2x3
KR102923602B1 (ko) 2019-05-31 2026-02-06 키에시 파르마슈티시 엣스. 피. 에이. P2x3 억제제로서 피리도피리미딘 유도체

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011041655A1 (en) * 2009-10-01 2011-04-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Quinazolin-4-amine derivatives; and methods of use
CN109641886A (zh) * 2015-11-25 2019-04-16 康威基内有限公司 双环bet布罗莫结构域抑制剂及其用途
CN112739699A (zh) * 2018-07-25 2021-04-30 费斯制药股份有限公司 作为组胺h4受体抑制剂的吡啶并嘧啶化合物

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Evaluation of substituted 6-arylquinazolin-4-amines as potent and selective inhibitors of cdc2-like kinases (Clk);Bryan T. Mott等;《Bioorganic & Medicinal Chemistry Letters》;20091003;第19卷;第6700-6705页 *
Ju Hou等.Design, synthesis, anti-tumor activity, and molecular modeling of quinazoline and pyrido[2,3-d]pyrimidine derivatives targeting epidermal growth factor receptor.《European Journal of Medicinal Chemistry》.2016,第118卷第276-289页. *
Potent and selective small molecule inhibitors of specific isoforms of Cdc2-like kinases (Clk) and dual specificity tyrosine-phosphorylation-regulated kinases (Dyrk);Andrew S. Rosenthal等;《Bioorganic & Medicinal Chemistry Letters》;20110304;第21卷;第3152-3158页 *
RN2062039-46-5等化合物;ACS;《REGISTRY(STN)》;20170131;第1-5页 *

Also Published As

Publication number Publication date
BR112021020279A2 (pt) 2021-12-14
US20220235060A1 (en) 2022-07-28
EP3976609A1 (en) 2022-04-06
JP2022534434A (ja) 2022-07-29
WO2020239953A1 (en) 2020-12-03
MX2021014116A (es) 2021-12-10
AU2020281924B2 (en) 2026-04-16
KR102923602B1 (ko) 2026-02-06
MA56020A (fr) 2022-04-06
US12606562B2 (en) 2026-04-21
AU2020281924A1 (en) 2021-12-16
KR20220016074A (ko) 2022-02-08
US20230212169A9 (en) 2023-07-06
CA3136024A1 (en) 2020-12-03
JP7797204B2 (ja) 2026-01-13
CN114222741A (zh) 2022-03-22

Similar Documents

Publication Publication Date Title
CN114269432B (zh) 作为p2x3抑制剂的氨基喹唑啉衍生物
JP7797204B2 (ja) P2x3阻害剤としてのピリドピリミジン誘導体
CN116745284A (zh) 作为p2x3抑制剂的酞嗪衍生物
EP4251617B1 (en) (aza)quinoline 4-amines derivatives as p2x3 inhibitors
RU2833037C2 (ru) Производные пиридопиримидинов в качестве ингибиторов p2x3
HK40060820B (en) Pyridopyrimidines derivatives as p2x3 inhibitors
HK40060820A (zh) 作为p2x3抑制剂的吡啶并嘧啶类衍生物
HK40091208A (en) Phthalazine derivatives as p2x3 inhibitors
HK40106991A (en) Amino quinazoline derivatives as p2x3 inhibitors
HK40062196B (en) Amino quinazoline derivatives as p2x3 inhibitors
HK40088660A (en) (aza)quinoline 4-amines derivatives as p2x3 inhibitors
HK40057265B (en) Amino quinazoline derivatives as p2x3 inhibitors
AU2024357784A1 (en) Compounds and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40060820

Country of ref document: HK

SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant